Trial reportAmerican journal of ophthalmology2014
In vitro susceptibility of filamentous fungal isolates from a corneal ulcer clinical trial.
Trial report in American journal of ophthalmology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Medical interventions for fungal keratitis.The Cochrane database of systematic reviews · 2015Pooled it
- Regression Discontinuity and Randomized Controlled Trial Estimates: An Application to The Mycotic Ulcer Treatment Trials.Ophthalmic epidemiology · 2018Trial
- Effect of Oral Voriconazole on Fungal Keratitis in the Mycotic Ulcer Treatment Trial II (MUTT II): A Randomized Clinical Trial.JAMA ophthalmology · 2016Trial
- Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis.Ophthalmology · 2014Trial
- Fungal keratitis: Does antifungal Resistance Influence the outcome?International ophthalmology · 2025Article
- Association between in vitro susceptibility and clinical outcomes in fungal keratitis.Journal of ophthalmic inflammation and infection · 2024Article
- Antifungal susceptibility profiles for fungal isolates from corneas and contact lenses in the United Kingdom.Eye (London, England) · 2024Article
- Rapid Point-of-Care Identification of Aspergillus Species in Microbial Keratitis.JAMA ophthalmology · 2023Article
- Antimicrobial resistance in topical treatments for microbial keratitis: protocol for a systematic review and meta-analysis.BMJ open · 2023Article
- Evaluation of antifungal susceptibility and clinical characteristics in fungal keratitis in a tertiary care center in North India.Indian journal of ophthalmology · 2022Article
- Diagnosing Fungal Keratitis and Simultaneously IdentifyingJournal of fungi (Basel, Switzerland) · 2022Article
- Human Corneal Epithelial Cells Internalize Aspergillus flavus Spores by Actin-Mediated Endocytosis.Infection and immunity · 2021Article
- Drug reservoir function of voriconazole impregnated human amniotic membrane: AnIndian journal of ophthalmology · 2021Article
- Sustained-release voriconazole-thermogel for subconjunctival injection in horses: ocular toxicity and in-vivo studies.BMC veterinary research · 2020Article
- Invasive Aspergillosis byJournal of fungi (Basel, Switzerland) · 2019Review
- Article
- Natamycin and Azithromycin Are SynergisticAntimicrobial agents and chemotherapy · 2018Article
- Antifungal Susceptibility, Morphological and Molecular Characterization of Lasiodiplodia theobromae Isolated from a Patient with Keratitis.Mycopathologia · 2018Article
- Contribution of ATPase copper transporters in animal but not plant virulence of the crossover pathogen Aspergillus flavus.Virulence · 2018Article
- In vivo confocal microscopy appearance ofThe British journal of ophthalmology · 2017Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
purposeTo describe the minimum inhibitory concentration (MIC) of fungal isolates to natamycin and voriconazole, and to compare these MICs to previous ocular susceptibility studies.
designExperimental laboratory study using isolates from a randomized clinical trial.
methodsThe Mycotic Ulcer Treatment Trial I was a randomized, double-masked, multicenter trial comparing topical natamycin and voriconazole for fungal keratitis treatment. Susceptibility testing to natamycin and voriconazole were performed according to Clinical and Laboratory Standards Institute methods. The relationship between organism and MIC was assessed. A literature review was performed to compare results to previous ocular susceptibility studies.
resultsOf the 323 patients enrolled in the trial, MICs were available for 221 (68%). Fusarium (n = 126) and Aspergillus species (n = 52) were the most commonly isolated organisms. MICs to natamycin and voriconazole were significantly different across all genera (P < .001). The MIC median (MIC50) and 90th percentile (MIC90) for natamycin were equal to or higher than voriconazole for all organisms except Curvularia species. Compared to other organisms, Fusarium species isolates had the highest MICs to voriconazole and Aspergillus flavus isolates had the highest MICs to natamycin. Our results were similar to previous reports except that the voriconazole MIC90 against Aspergillus species was 2-fold higher and the natamycin MIC90 against Aspergillus fumigatus was 4-fold higher in our study.
conclusionIn this large susceptibility study, Fusarium isolates were least susceptible to voriconazole and A flavus isolates were least susceptible to natamycin when compared to other filamentous fungi. In the future, susceptibility testing may help guide therapy if performed in a timely manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.